Quantifying US healthcare provider preferences for the treatment of post-transplant cytomegalovirus infection using a discrete choice experiment
Authors:
- Zoe RaglowZRZoe Raglow
- Ana María RodriguezARAna María Rodriguez
- Ana Sofia Oliveira GonçalvesAGAna Sofia Oliveira Gonçalves
- Mickael Henry-SzatkowskiMHMickael Henry-Szatkowski
- France Ginchereau SowellFSFrance Ginchereau Sowell
- Michael BullanoMBMichael Bullano
- Daniele K. GeloneDGDaniele K. Gelone
- Bob G. SchultzBSBob G. Schultz
Open Access
- 4 March 2026
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 42 (3) , 529-539
Abstract
Post-transplant cytomegalovirus (CMV) infection is one of the most common viral infections experienced by transplant recipients1,2. Despite prevention strategies, CMV infection continues to occur w...Keywords
Funding Information
- Takeda Pharmaceuticals USA, Inc.
This publication has 21 references indexed in Scilit:
- Global inequities in organ transplantation, 2008–2023: trends, unmet need, and policy implicationseClinicalMedicine, 2026
- Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapiesThe Lancet Infectious Diseases, 2025
- Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipientsCochrane Database of Systematic Reviews, 2022
- Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantationJournal of Medical Economics, 2022
- Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical TrialClinical Infectious Diseases, 2021
- American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2021
- Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal FunctionTransplantation and Cellular Therapy, 2020
- Drug–drug interactions in patients receiving hematopoietic stem cell transplantationExpert Opinion on Drug Metabolism & Toxicology, 2018
- Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task ForceValue in Health, 2016
- Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task ForceValue in Health, 2013